Skip to main content
. 2024 Jan 18;30(7):1240–1247. doi: 10.1158/1078-0432.CCR-23-2513

Figure 3.

Figure 3. Overall survival (OS). A, Olaparib alone. B, Olaparib plus durvalumab. NE, not estimable.

Overall survival (OS). A, Olaparib alone. B, Olaparib plus durvalumab. NE, not estimable.